Showing 2891-2900 of 3039 results for "".
- ProtoKinetix AAGP in Phase 3 Retinal Replacement Programhttps://modernod.com/news/protokinetix-aagp-in-phase-3-retinal-replacement-program/2476493/ProtoKinetix updated its stockholders regarding phase 3 of testing using AAGP in retinal cell replacement therapy at the University of British Columbia. The study is now using 2 animal models and a significantly larger number of animals in both control and AAGP treated groups for a longer
- Bausch + Lomb Announces New Divisional Leadership in the UShttps://modernod.com/news/bausch-lomb-announces-new-divisional-leadership-in-the-us/2476487/Bausch + Lomb announced the appointment of new leadership in its Pharmaceuticals and Consumer Health Care divisions in the United States. Yolande Barnard, formerly the vice president, marketing and sales, U.S. Neurology, Bausch Health, will now serve as vice president and general manager,
- Innovent Announces First Patient Dosed in a Phase 1 Clinical Trial of IBI302 for the Treatment of Wet AMDhttps://modernod.com/news/innovent-announces-first-patient-dosed-in-a-phase-1-clinical-trial-of-ibi302-for-the-treatment-of-wet-amd/2476478/Innovent Biologics announced that the first patient has been successfully dosed in a phase 1 clinical trial of IBI302, a novel recombinant fully human bispecific fusion protein targeting both vascular endothelium growth factor (VEGF) and complement proteins, for the treatment of wet age-related m
- Ophthotech Changes Name to Iveric bio as it Transitions to Gene Therapy Companyhttps://modernod.com/news/ophthotech-changes-name-to-iveric-bio-as-it-transitions-to-gene-therapy-company/2476473/Ophthotech announced that as part of its transition strategy to focus on discovering and developing novel gene therapy solutions to treat orphan inherited retinal diseases (IRDs) with unmet medical needs, the company
- I-MED Pharma Becomes Authorized Canadian Distributor for OrCam MyEye 2https://modernod.com/news/i-med-pharma-becomes-authorized-canadian-distributor-for-orcam-myeye-2/2476463/I-MED Pharma, a Canadian company specializing in dry eye diagnosis and management, announced the signing of an authorized Canadian distribution agreement with OrCam for its MyEye 2 assistive technology device for the blind and visually impaired. The OrCam MyEye 2 is a tiny, portable, artif
- Alcon Debuts as Independent, Publicly Traded Companyhttps://modernod.com/news/alcon-debuts-as-independent-publicly-traded-company/2476453/After 8 years under Novartis ownership, Alcon is officially an independent, publicly traded company. On Tuesday, Alcon completed its separation from Novartis and its shares begin trading on the SIX Swiss Exchange and New York Stock Exchange under the symbol “ALC.” American depositary recei
- Asepticys Files 510k Submission With FDA for TriFlect Disinfection Technologyhttps://modernod.com/news/asepticys-files-510k-submission-with-fda-for-triflect-disinfection-technology/2476450/Asepticys announced the completion of multisite human clinical trials for Asepticys’ novel contact lens care solution containing TriFlect technology. The company has submitted a 510(k) application to the FDA. The clinical trials involved over 320 patients at 12 sites across
- Alcon Announces Timothy Stonesifer as Chief Financial Officerhttps://modernod.com/news/alcon-announces-timothy-stonesifer-as-chief-financial-officer/2476432/Alcon announced that Timothy C. Stonesifer will join the company as its new Senior Vice President and Chief Financial Officer, in conjunction with the company’s April 9 spinoff from Novartis. He will report directly to David Endicott, Alcon’s Chief Executive Officer, and bec
- Ocular Therapeutix Announces Supplemental NDA Accepted by FDA for Dextenzahttps://modernod.com/news/ocular-therapeutix-announces-supplemental-nda-accepted-by-fda-for-dextenza/2476429/Ocular Therapeutix announced the FDA has accepted the filing of the supplemental new drug application (sNDA) for Dextenza (dexamethasone ophthalmic insert) to include the treatment of ocular inflammation following ophthalmic surgery in its label. The notice of acceptance confirms the FDA has comp
- Heidelberg Engineering Introduces the GMPE Hood Glaucoma Report for Spectralis OCThttps://modernod.com/news/heidelberg-engineering-introduces-the-gmpe-hood-glaucoma-report-for-spectralis-oct/2479582/Heidelberg Engineering announced that the Hood Glaucoma Report is now available with a software update within the Spectralis OCT Glaucoma Module Premium Edition (GMPE). The GMPE Hood Glaucoma Report highlights